DRUG · Mapped RxNorm record
Eribulin
Normalized identity: eribulinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
NCT02061085
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedMonotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Neoplasmverified · MONDO: breast neoplasm
Metastasisunresolved
Interventions
EribulinDRUG · verified · RxNorm: eribulin
Sponsors & collaborators
MedSIRlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02061085 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.